Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart oxygen machine may ease walking for lung disease patients

NCT ID NCT06465654

Symptom relief Sponsor: Janne Hastrup Jensen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new automatic oxygen device in 29 people with fibrotic lung disease (scarred lungs). The device automatically adjusts oxygen flow during walking to keep oxygen levels steady. The goal was to see if it reduces breathlessness compared to the usual fixed oxygen dose. Participants did two walking tests with each method to compare results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Jun 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Verified diagnosis of fibrotic interstitial lung disease * Desaturation during a recent (6 months) 6-minute walk test below 88% on atmospheric air or during an incremental shuttle walking test * Able to walk at least 50 meters * Self-reported stable respiratory symptoms in the previous 2 weeks * Age ≥ 18 years * Cognitively able to understand and participate in the study * Written informed consent Exclusion Criteria: * Long term oxygen treatment * A pulmonary or cardiac condition other than fibrotic interstitial lung disease limiting exercise performance * Unstable heart condition or symptomatic stenotic valve disease * Any physical condition limiting exercise performance. * Smoking the previous 24 hours * Pregnancy * Anaemia, haemoglobin \< 7.3 mmol/l (women) or \< 8.3 mmol/l (men)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrosis lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibrosis lung Respiratory therapy

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.